Latest Breaking News On - Harout semerjian - Page 2 : comparemela.com

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
India
Leo-vartorella
Harout-semerjian
Exchange-commission
Company-annual-report-on-form
Nasdaq
Glycomimetics-inc
Chief-executive-officer
Southern-mediterranean
Middle-east
Acute-myeloid-leukemia

GlycoMimetics (GLYC) Reports Positive Initial Safety and Pharmacokinetic Results from Phase 1a Study of GMI-1687

GlycoMimetics (GLYC) Reports Positive Initial Safety and Pharmacokinetic Results from Phase 1a Study of GMI-1687
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Harout-semerjian
Glycomimetics-inc
Nasdaq
Chief-executive-officer

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference

GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
London
City-of
Leo-vartorella
Harout-semerjian
Glycomimetics-inc
Nasdaq
Chief-executive-officer
Jefferies-london-healthcare-conference
Biohealth-capital

GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Call Transcript

Operator: Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode.

San-diego
California
United-states
Boston
Massachusetts
Dana-farber-cancer-institute
American
Debora-peralta
Harout-semerjian
Gaetano-bonifacio
John-horan
Christian-dinneen

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023

Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory Acute Myeloid Leukemia on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end.

China
Chinese
Harout-semerjian
Glycomimetics-inc
Nasdaq
National-cancer-institute
Company-annual-report-on-form
Drug-administration
Chinese-national-medical-products-administration
European-medicines-agency
Alliance-for-clinical-trials-in-oncology
Exchange-commission